leisure time -WSS

leisure time

author：hotspot 2025-09-03 09:18:25 - browse：5

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Former reverend arrested for allegedly killing 8

WSS

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Why patients can’t get everything they want on drug pricing

What it's like to live with paralysis for one psychologist

FDA approves updated Covid vaccines

Acelyrin, a rare IPO success, stumbles in its first big test

How to make the FDA’s new prescription one

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Affirmative action in medical school literally saved lives

Will the IRA bring competition to the biologics market?

How to save PrEP access — and even expand it

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Jerome Adams on the need for new antivirals for Covid

Acelyrin, a rare IPO success, stumbles in its first big test

What does generative AI mean for health care? We asked experts

Generate Biomedicines machine learning biotech raises $273M

Virginia high school admissions case could be legal follow

FDA proposes changes to key medical devices approval pathway

focus

In the gardens at Boston Children's Hospital, families find sanctuary

Truvian presents data for its desktop blood

New Covid vaccine is recommended for everyone 6 months or older

UHS says company favors patients whose insurance pays more

UHS says company favors patients whose insurance pays more

Acelyrin, a rare IPO success, stumbles in its first big test

Wikipedia

leisure time

leisure time

focus